Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials
- 1 June 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (16), 2692-2696
- https://doi.org/10.1200/jco.2008.19.5081
Abstract
Purpose With the aim of improving patient selection for phase I trials, we previously performed a retrospective analysis of 212 phase I oncology patients where we were able to develop a prognostic score predicting overall survival (OS). This prospective study was performed to test the validity of the prognostic score. Patients and Methods On the basis of our retrospective multivariate analysis, three factors were associated with poor survival (albumin < 35 g/L, lactate dehydrogenase [LDH] > upper limit of normal [ULN], and > two sites of metastases). We integrated these into a prognostic score ranging from 0 to 3 and analyzed this score in a prospectively selected cohort of 78 patients enrolled onto phase I trials. Results All patients had progressive disease before study entry. The median age was 56 years (range, 18 to 79 years). After a median follow-up time of 27.3 weeks, patients with a prognostic score of 0 to 1 (n = 43) had superior OS (33.0 weeks; 95% CI, 24 to 42 weeks) compared with patients with a score of 2 to 3 (n = 35; 15.7 weeks; 95% CI, 11 to 21 weeks). Our multivariate analysis confirmed that our prognostic score was an independent marker for OS, with a hazard ratio of 1.4 (95% CI, 1.02 to 1.9; P = .036). Conclusion This is the first prospective analysis confirming that a prognostic score based on objective markers, including albumin less than 35 g/L, LDH more than ULN, and more than two sites of metastasis, is a helpful tool in the process of patient selection for phase I trial entry.Keywords
This publication has 20 references indexed in Scilit:
- 90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial?European Journal of Cancer, 2008
- Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden HospitalEuropean Journal of Cancer, 2008
- Multi-Institutional Phase I Trials of Anticancer AgentsJournal of Clinical Oncology, 2008
- Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave RoussyAnnals of Oncology, 2007
- Prognostic factors among cancer patients with good performance status screened for phase I trialsInvestigational New Drugs, 2007
- Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret HospitalBMC Cancer, 2006
- Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapyBritish Journal of Cancer, 2005
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002The New England Journal of Medicine, 2005
- Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical TrialsJAMA, 2004
- Phase I Clinical Trial Design in Cancer Drug DevelopmentJournal of Clinical Oncology, 2000